The opening plenary session of the World Federation of Hemophilia featured von Willebrand disease expert Dr. Peter Lenting, who reported on “Novel Treatment Options in von Willebrand Disease.” He reported on a case study in which emicizumab was used to successfully treat a type 3 VWD patient with anti-VWF inhibitors. The case study presentation appears here: Weyand AC, Flood VH, JA Shavit, Pipe SW. Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies. Blood Advances 2019. DOI 10.1182.
May 30 2022
Comments (1)Bleeding Disorders
Interesting study George,
Interesting study George, thanks for sharing. There was much discussion at the WFH meeting on the relative lack of innovation in VWD treatments compared to hemophilia, and maybe this is a start towards improved care of VWD patients as well.